1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
651C496ADDFB7F03A00258B2D0035E107
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/building-foundational-global-function-for-reviewing-ime-grants?opendocument
18
19opendocument
203.236.142.143
21
22
23best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services ╗ Medical AffairsMedical Education

Building a Foundational Global Function for Reviewing IME Grants

ID: POP-382


Features:

8 Info Graphics

19 Data Graphics

250+ Metrics

52 Narratives


Pages: 36


Published: 2024


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Independent medical education (IME) grants programs serve as a unique platform for biopharma organizations to support high-quality, evidence-based educational initiatives for healthcare professionals, patients, payers, and systems worldwide. To fulfill this important mission for the organization, a structured and efficient management approach toward IME grants is crucial to ensure optimal resource utilization and impactful educational outcomes.

Best Practices, LLC conducted this benchmarking study to explore how biopharma organizations can optimize their grants review process to identify and address critical educational gaps proactively. The report examines the key roles and activities of global IME groups, focusing on structuring grant review processes to maximize IME budgets and ensure the highest possible impact.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Medical Device; Biotech; Health Care; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; Baxter International; Dermavant Sciences; GRAIL; Grifols; Merck; OTSUKA; Sage Therapeutics; Sanofi; Vertex Pharmaceuticals

Study Snapshot

Best Practices, LLC engaged 13 Medical leaders from 13 companies spanning 22 therapeutic areas through a comprehensive benchmarking survey. Follow-up interviews were conducted to gain deeper insights into the data and approaches described. Most participants represented mid-cap biopharma organizations.

Key topics covered in this report include:

  • IME Grants Review Process and Systems
  • Staffing Levels and Alignment for Grant Management
  • Grants Program Measurement and Performance
  • Field Medical Support for IME
  • IME Grants Budget Allocation
  • Future Trends and Lessons Learned

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • IME Grants Process Milestones: Submission, Review and Decision phases are used by all organizations to track the IME Grants process, and 73% also track the Discussion phase.
  • IME Grants Budget Allocation: The North American market receives 81% of IME Grants’ overall organizational funding. Most of the remaining funds are allocated to the European (9%) and APAC (4%) markets.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Study Background and Benchmark ClassPg. 3-5
II.
Executive SummaryPg. 6-10
III.
IME Grant Review Phases and MilestonesPg. 11-19
IV.
Technology and Innovation in IME Grant ReviewPg. 20-24
V.
Global IME Structure & Grants ManagementPg. 25-33
VI.
Participant DemographicsPg. 34-35
VII.
About Best Practices, LLCPg. 36

    List of Charts & Exhibits

    I. Study Background and Benchmark Class

    • Study background
    • Benchmark study partners

    II. Executive Summary

    • One-page study summary
    • Key study insights for Medical leadership

    III. IME Grant Review Phases and Milestones

    • Milestones and timelines employed by benchmark organizations to manage the IME grants process
    • Average duration for each IME grant review phase
    • Key elements to include on grant evaluation checklists
    • Criteria for choosing offline reviews versus live meetings
    • Information provided by IME operations teams to committees as a pre-read and during meetings
    • Grant review approaches
    • Number of global IME staff members dedicated to grant management and total grants processed by these FTEs
    • Key performance indicators for evaluating overall grants management effectiveness

    IV. Technology and Innovation in IME Grant Review

    • Software used by Medical Education groups to evaluate and manage the grants review process and the tenure of use
    • Functions or work streams with shared access to the system
    • Utilization of field medical staff to supplement the distribution of invitations for company-supported IME programs
    • Key strengths and major areas for improvement in current IME performance

    V. Global IME Structure and Grants Management

    • Allocation of the total organizational budget for IME grants across key markets
    • Teams responsible for key activities in the grants review process
    • Alignment of global IME staff members within the organization
    • Total number of FTEs employed in the global IME group
    • Percentage of time spent on IME activities
    • Most important trends in global governance for IME leaders to monitor over the next 2-3 years
    • Top lessons for running an efficient and impactful grants program

    VI. Participant Demographics

    • Therapeutic areas represented by benchmark partners